Compare · POCI vs TMDX
POCI vs TMDX
Side-by-side comparison of Precision Optics Corporation Inc. (POCI) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both POCI and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.92B, about 60.0x POCI ($48.7M).
- Over the past year, POCI is down 3.4% and TMDX is down 21.1% - POCI leads by 17.7 points.
- POCI has been more active in the news (5 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (19 ratings vs 0 for POCI).
- Company
- Precision Optics Corporation Inc.
- TransMedics Group Inc.
- Price
- $4.49+5.15%
- $84.32+2.48%
- Market cap
- $48.7M
- $2.92B
- 1M return
- +6.90%
- +4.41%
- 1Y return
- -3.44%
- -21.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 2
- Recent ratings
- 0
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest POCI
- SEC Form 4 filed by Senior VP - Sales & Marketing Thier Peter Richard
- SEC Form 3 filed by new insider Thier Peter Richard
- Precision Optics Appoints Peter Thier as Senior Vice President of Sales and Marketing
- Precision Optics to Participate in the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, 2026
- Chief Financial Officer Coll Wayne M was granted 1,257 shares, increasing direct ownership by 3% to 38,064 units (SEC Form 4)
- Precision Optics to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
- Precision Optics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
- Precision Optics Reports Third Quarter Fiscal Year 2026 Financial Results
- SEC Form 10-Q filed by Precision Optics Corporation Inc.
- New insider Needham Investment Management Llc claimed ownership of 3,341,100 shares (SEC Form 3)
Latest TMDX
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)